Kyverna Therapeutics, Inc. (KYTX) AI Stock Analysis

• Market Cap: $156.98M
• Dividend Yield: N/A
• Average Volume (3M): 257.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: N/A
• EPS Growth: -39.69%
• Country: US
• Employees: 112
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.97
• Shares Outstanding: 43,245,667
• 10 Day Avg. Volume: 255,013
• 30 Day Avg. Volume: 257,250
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.47
• Enterprise Value/Revenue: -36.10
• Enterprise Value/Gross Profit: 34.19
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $19.75
• Price Target Upside: 401.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 36 Underperform
• Price Target: ―

Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company's technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock's performance.

Positive Factors

Clinical Trial Success

The Phase 3 trial is over 90% powered to demonstrate superiority over the standard of care as the comparator.

Efficacy and Safety

Management highlighted the encouraging safety profile of KYV-101, having recently reached the milestone of treating the 100th patient, which continues to build a strong safety database.

Regulatory and Market Leadership

Kyverna is poised to have the first FDA approved CAR-T for the treatment of an autoimmune disease, which could secure the company’s position as a leader in the field.

Negative Factors

Market Uncertainty

The company's commercial strategy supports a rapid and efficient launch in myasthenia gravis and presents a first-to-market opportunity in stiff person syndrome that may be larger than initially expected.

Regulatory Timeline

Patient enrollment in the Phase III portion is expected to begin by the end of 2025.

Kyverna Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

How the Company Makes Money

Kyverna Therapeutics makes money primarily through the development and commercialization of its cell therapy products. The company may generate revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which can include upfront payments, milestone payments, and royalties on sales of co-developed therapies. Additionally, Kyverna might engage in licensing agreements for its proprietary technologies, further contributing to its revenue streams. As a biotechnology firm, Kyverna may also secure funding from investors and grants to support its research and development efforts.

Kyverna Therapeutics, Inc. Financial Statement Overview

Summary

Kyverna Therapeutics, Inc. faces significant financial challenges with consistent losses and zero revenue in the most recent period. The balance sheet reflects a strong equity position, but profitability remains a concern. Cash flow analysis indicates liquidity constraints despite recent financing activities. Improvement in revenue generation and operational efficiencies is crucial for financial health.

Income Statement

Kyverna Therapeutics, Inc. shows significant challenges in generating revenue with total revenue at zero for the latest period. Net profit margins are negative, reflecting continuous losses over the years. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. The revenue growth rate cannot be calculated due to zero revenue, highlighting the company's struggle in revenue generation.

Balance Sheet

The company has a strong equity base with a low debt-to-equity ratio due to significant stockholders' equity. However, the equity ratio is high, and the company is not highly leveraged, which is a positive sign. Return on equity is negative, reflecting the ongoing losses impacting shareholder returns. Overall, while the company maintains a relatively stable balance sheet, the profitability aspect is weak.

Cash Flow

Free cash flow is negative, indicating that the company is not generating enough cash to cover its capital expenditures. Operating cash flow is also negative, underscoring operational challenges. However, the company has managed significant financing cash inflows, which may provide some liquidity buffer. The ratio of operating cash flow to net income and free cash flow to net income is not favorable, showing cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.02M	0.00	0.00	7.03M	5.66M
Gross Profit	-2.14M	-2.13M	-1.71M	5.97M	5.07M
EBITDA	-162.62M	-125.20M	-58.47M	-27.78M	-25.76M
Net Income	-158.70M	-127.48M	-60.37M	-28.89M	-26.35M
Balance Sheet
Total Assets	226.51M	304.64M	75.19M	66.92M	85.49M
Cash, Cash Equivalents and Short-Term Investments	211.68M	285.98M	57.54M	51.32M	76.07M
Total Debt	5.92M	8.24M	9.08M	10.56M	5.55M
Total Liabilities	42.13M	38.06M	26.02M	140.92M	131.74M
Stockholders Equity	184.38M	266.59M	49.18M	-74.00M	-46.25M
Cash Flow
Free Cash Flow	-142.25M	-116.45M	-53.03M	-36.88M	-23.44M
Operating Cash Flow	-141.41M	-114.25M	-52.41M	-36.11M	-22.16M
Investing Cash Flow	64.64M	-160.90M	-8.79M	-14.10M	-1.29M
Financing Cash Flow	-1.43M	337.11M	58.12M	11.88M	72.52M

Kyverna Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYTX, the sentiment is Positive. The current price of 3.94 is above the 20-day moving average (MA) of 3.56, above the 50-day MA of 3.58, and above the 200-day MA of 3.19, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 59.44 is Neutral, neither overbought nor oversold. The STOCH value of 48.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYTX.

Kyverna Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.29B	4.66	-20.95%	6.01%	10.84%	8.15%
CCCC	54 Neutral	$190.03M	―	-52.99%	―	16.55%	16.73%
ELUT	47 Neutral	$85.21M	―	149.62%	―	-5.22%	82.06%
ZNTL	46 Neutral	$127.68M	―	-49.55%	―	-33.76%	17.10%
CLYM	41 Neutral	$157.89M	―	-22.92%	―	―	67.69%
KYTX	36 Underperform	$156.98M	―	-61.29%	―	―	-39.69%
VOR	33 Underperform	$244.50M	―	-125.43%	―	―	-686.13%

Kyverna Therapeutics, Inc. Corporate Events

Kyverna Therapeutics Sets 2025 Strategic Priorities for Growth

Kyverna Therapeutics announces its strategic priorities for 2025, highlighting its focus on advancing the KYV-101 CD19 CAR T-cell therapy through late-stage development and commercialization for autoimmune diseases. The company aims to achieve a first-to-market position with KYV-101 for stiff person syndrome, with a BLA filing targeted for 2026, while also expanding its pipeline with KYV-102 to enhance CAR T accessibility. The company is focusing on capital-efficient growth and has a cash runway into 2027 to support its strategic goals.